Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


06.11.2017

2 Am J Epidemiol
1 Am J Ind Med
2 Am J Respir Crit Care Med
1 Ann Oncol
7 Ann Thorac Surg
3 Anticancer Res
1 Arch Bronconeumol
1 BMC Cancer
1 Cancer Cell
2 Cancer Lett
8 Cancer Res
1 Cancer Sci
1 Clin Cancer Res
1 Clin Lung Cancer
1 Eur J Cancer
1 Eur Respir J
3 Int J Cancer
1 J Clin Invest
2 J Clin Oncol
1 J Natl Cancer Inst
5 J Thorac Oncol
1 Lancet Oncol
3 Lung Cancer (Auckl)
1 Mol Cancer Ther
2 Mol Carcinog
2 Nat Rev Cancer
5 PLoS One
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Epidemiol

  1. HANSEN MS, Licaj I, Braaten T, Langhammer A, et al
    Sex Differences in Risk of Smoking- Associated Lung Cancer: Results From a Cohort of 600,000 Norwegians.
    Am J Epidemiol. 2017 Oct 26. doi: 10.1093.
    PubMed     Text format     Abstract available

  2. PUN VC, Kazemiparkouhi F, Manjourides J, Suh HH, et al
    Long-Term PM2.5 Exposure and Respiratory, Cancer, and Cardiovascular Mortality in Older US Adults.
    Am J Epidemiol. 2017;186:961-969.
    PubMed     Text format     Abstract available


    Am J Ind Med

  3. EL ZOGHBI M, Salameh P, Stucker I, Paris C, et al
    Prevalence of occupational exposure to asbestos and crystalline silica according to phenotypes of lung cancer from the CaProMat study: A case-only study.
    Am J Ind Med. 2017 Oct 31. doi: 10.1002/ajim.22765.
    PubMed     Text format     Abstract available


    Am J Respir Crit Care Med

  4. DUBINETT SM, Spira AE
    Impact of COPD on Immune-based Treatment for Lung Cancer: Moving Towards Disease Interception.
    Am J Respir Crit Care Med. 2017 Oct 26. doi: 10.1164/rccm.201710-2065.
    PubMed     Text format    

  5. KATHURIA H, Detterbeck FC, Fathi JT, Fennig K, et al
    Stakeholder Research Priorities for Smoking Cessation Interventions within Lung Cancer Screening Programs. An Official American Thoracic Society Research Statement.
    Am J Respir Crit Care Med. 2017;196:1202-1212.
    PubMed     Text format     Abstract available


    Ann Oncol

  6. OTSUBO K, Seki N, Nakanishi Y, Okamoto I, et al
    Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small cell lung cancer.
    Ann Oncol. 2017 Oct 23. doi: 10.1093.
    PubMed     Text format    


    Ann Thorac Surg

  7. SAWANT A, Mankar H, Chatterjee A, Pramesh CS, et al
    VATS Versus Open Lobectomy: Need for a Prospective Trial.
    Ann Thorac Surg. 2017;103:690-691.
    PubMed     Text format    

  8. KAYAWAKE H, Chen-Yoshikawa TF, Oda H, Motoyama H, et al
    Complications of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.
    Ann Thorac Surg. 2017;104:e363-e365.
    PubMed     Text format     Abstract available

  9. YAMANASHI K, Okumura N, Otsuki Y, Matsuoka T, et al
    Stapler-Based Thoracoscopic Basilar Segmentectomy.
    Ann Thorac Surg. 2017;104:e399-e402.
    PubMed     Text format     Abstract available

  10. SHIMIZU K, Nagashima T, Yajima T, Ohtaki Y, et al
    Thoracoscopic Medial-Basal Segment Segmentectomy.
    Ann Thorac Surg. 2017;104:e403-e406.
    PubMed     Text format     Abstract available

  11. SHIMIZU K, Mogi A, Yajima T, Nagashima T, et al
    Thoracoscopic Subsuperior Segment Segmentectomy.
    Ann Thorac Surg. 2017;104:e407-e410.
    PubMed     Text format     Abstract available

  12. BROWN LM, Cooke DT, David EA
    Adjuvant Chemotherapy Does Not Improve Survival for Lung Cancer With Chest Wall Invasion.
    Ann Thorac Surg. 2017 Oct 24. pii: S0003-4975(17)30973.
    PubMed     Text format     Abstract available

  13. DHANASOPON AP, Salazar MC, Hoag JR, Rosen JE, et al
    Fate of Pneumonectomy Patients Variably Captured by Non-Small Cell Lung Cancer Staging System.
    Ann Thorac Surg. 2017 Oct 24. pii: S0003-4975(17)30978.
    PubMed     Text format     Abstract available


    Anticancer Res

  14. SANOMACHI T, Suzuki S, Kuramoto K, Takeda H, et al
    Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.
    Anticancer Res. 2017;37:6177-6188.
    PubMed     Text format     Abstract available

  15. MULLER L, Radtke A, Decker J, Koch M, et al
    The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines.
    Anticancer Res. 2017;37:6341-6345.
    PubMed     Text format     Abstract available

  16. FIALA O, Hosek P, Pesek M, Finek J, et al
    Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.
    Anticancer Res. 2017;37:6469-6476.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  17. AGUIAR F, Fernandes G, Queiroga H, Machado JC, et al
    Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population.
    Arch Bronconeumol. 2017 Oct 24. pii: S0300-2896(17)30265.
    PubMed     Text format     Abstract available


    BMC Cancer

  18. YANG X, Pei S, Wang H, Jin Y, et al
    Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73.
    BMC Cancer. 2017;17:255.
    PubMed     Text format     Abstract available


    Cancer Cell

  19. CLARK SJ, Molloy PL
    Smoke-Induced Changes to the Epigenome Provide Fertile Ground for Oncogenic Mutation.
    Cancer Cell. 2017;32:278-280.
    PubMed     Text format     Abstract available


    Cancer Lett

  20. LIU X, Chen B, You W, Xue S, et al
    The membrane bile acid receptor TGR5 drives cell growth and migration via activation of the JAK2/STAT3 signaling pathway in non-small cell lung cancer.
    Cancer Lett. 2017 Oct 23. pii: S0304-3835(17)30652.
    PubMed     Text format     Abstract available

  21. WANG ZQ, He CY, Hu L, Shi HP, et al
    Long noncoding RNA UCA1 promotes tumour metastasis by inducing GRK2 degradation in gastric cancer.
    Cancer Lett. 2017 Aug 23. pii: S0304-3835(17)30490.
    PubMed     Text format     Abstract available


    Cancer Res

  22. MCFARLAND CD, Yaglom JA, Wojtkowiak JW, Scott JG, et al
    The Damaging Effect of Passenger Mutations on Cancer Progression.
    Cancer Res. 2017;77:4763-4772.
    PubMed     Text format     Abstract available

  23. YOUNG A, Ngiow SF, Madore J, Reinhardt J, et al
    Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis.
    Cancer Res. 2017 Jun 26. pii: canres.0393.2017.
    PubMed     Text format     Abstract available

  24. TAKAGI S, Ishikawa Y, Mizutani A, Iwasaki S, et al
    LSD1 Inhibitor T-3775440 Inhibits SCLC Cell Proliferation by Disrupting LSD1 Interactions with SNAG Domain Proteins INSM1 and GFI1B.
    Cancer Res. 2017;77:4652-4662.
    PubMed     Text format     Abstract available

  25. NG KY, Chan LH, Chai S, Tong M, et al
    TP53INP1 down-regulation activates a p73-dependent DUSP10/ERK signaling pathway to promote metastasis of hepatocellular carcinoma.
    Cancer Res. 2017 Jul 3. pii: canres.3456.2016.
    PubMed     Text format     Abstract available

  26. MURLIDHAR V, Reddy RM, Fouladdel S, Zhao L, et al
    Poor Prognosis Indicated by Venous Circulating Tumor Cell Clusters in Early-Stage Lung Cancers.
    Cancer Res. 2017;77:5194-5206.
    PubMed     Text format     Abstract available

  27. LIU Y, Li Y, Wang X, Liu F, et al
    Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
    Cancer Res. 2017;77:5068-5076.
    PubMed     Text format     Abstract available

  28. TILL J, Yoon C, Kim BJ, Roby KC, et al
    Oncogenic KRAS and p53 loss drive gastric tumorigenesis in mice that can be attenuated by E-cadherin expression.
    Cancer Res. 2017 Jul 31. pii: canres.0061.2017.
    PubMed     Text format     Abstract available

  29. ZUO H, Ueland PM, Midttun O, Vollset SE, et al
    Results from the European Prospective Investigation into Cancer and Nutrition (EPIC) link vitamin B6 catabolism and lung cancer risk.
    Cancer Res. 2017 Oct 25. pii: canres.1923.2017.
    PubMed     Text format     Abstract available


    Cancer Sci

  30. OKABE H, Aoki K, Yogosawa S, Saito M, et al
    Downregulation of CD24 suppresses bone metastasis of lung cancer.
    Cancer Sci. 2017 Nov 2. doi: 10.1111/cas.13435.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  31. ARBOUR KC, Jordan EJ, Kim HR, Dienstag J, et al
    Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer.
    Clin Cancer Res. 2017 Oct 31. pii: clincanres.1841.2017.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  32. NOMA D, Inamura K, Matsuura Y, Hirata Y, et al
    Prognostic Effect of Lymphovascular Invasion on TNM Staging in Stage I Non-Small-cell Lung Cancer.
    Clin Lung Cancer. 2017 Jun 20. pii: S1525-7304(17)30174.
    PubMed     Text format     Abstract available


    Eur J Cancer

  33. IIJIMA Y, Hirotsu Y, Amemiya K, Ooka Y, et al
    Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
    Eur J Cancer. 2017;86:349-357.
    PubMed     Text format     Abstract available


    Eur Respir J

  34. PARIS C, Do P, Mastroianni B, Dixmier A, et al
    Association between lung cancer somatic mutations and occupational exposure in never-smokers.
    Eur Respir J. 2017;50.
    PubMed     Text format     Abstract available


    Int J Cancer

  35. WU Y, Shi H, Jiang M, Qiu M, et al
    The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
    Int J Cancer. 2017;141:2562-2570.
    PubMed     Text format     Abstract available

  36. SATTERFIELD L, Shuck R, Kurenbekova L, Allen-Rhoades W, et al
    miR-130b directly targets ARHGAP1 to drive activation of a metastatic CDC42-PAK1-AP1 positive feedback loop in Ewing sarcoma.
    Int J Cancer. 2017;141:2062-2075.
    PubMed     Text format     Abstract available

  37. KIM J, Field A, Schultz KAP, Hill DA, et al
    The prevalence of DICER1 pathogenic variation in population databases.
    Int J Cancer. 2017;141:2030-2036.
    PubMed     Text format     Abstract available


    J Clin Invest

  38. SHENOLIKAR S
    A SMAP in the face for cancer.
    J Clin Invest. 2017;127:2048-2050.
    PubMed     Text format     Abstract available


    J Clin Oncol

  39. GROSSO F, Steele N, Novello S, Nowak AK, et al
    Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
    J Clin Oncol. 2017;35:3591-3600.
    PubMed     Text format     Abstract available

  40. WHITNEY RL, Bell JF, Tancredi DJ, Romano PS, et al
    Hospitalization Rates and Predictors of Rehospitalization Among Individuals With Advanced Cancer in the Year After Diagnosis.
    J Clin Oncol. 2017;35:3610-3617.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  41. ZHOU B, Wang GZ, Wen ZS, Zhou YC, et al
    Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
    J Natl Cancer Inst. 2017 Jul 17. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  42. LEE JS, Hur JY, Kim HJ, Lee KY, et al
    A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non-Small Cell Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e179-e181.
    PubMed     Text format    

  43. HENNINGFIELD MF, Adjei AA
    Lung Cancer Awareness Month-A Lot of Progress, But More Work Needs to Be Done.
    J Thorac Oncol. 2017;12:1603-1605.
    PubMed     Text format    

  44. RICORDEL C, Llamas-Gutierrez F, Chiforeanu D, Lena H, et al
    Large Cell Neuroendocrine Lung Carcinoma Transformation as an Acquired Resistance Mechanism to Osimertinib.
    J Thorac Oncol. 2017;12:e184-e186.
    PubMed     Text format    

  45. WU B, Gu X, Zhang Q
    Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy.
    J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32851.
    PubMed     Text format     Abstract available

  46. PARK SE, Lee SH, Ahn JS, Ahn MJ, et al
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32850.
    PubMed     Text format     Abstract available


    Lancet Oncol

  47. SHAW AT, Felip E, Bauer TM, Besse B, et al
    Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
    Lancet Oncol. 2017 Oct 23. pii: S1470-2045(17)30680.
    PubMed     Text format     Abstract available


    Lung Cancer (Auckl)

  48. MUDAD R, Patel MB, Margunato-Debay S, Garofalo D, et al
    Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting.
    Lung Cancer (Auckl). 2017;8:179-190.
    PubMed     Text format     Abstract available

  49. CASCONE R, Carlucci A, Pierdiluca M, Santini M, et al
    Prognostic value of soluble major histocompatibility complex class I polypeptide-related sequence A in non-small-cell lung cancer - significance and development.
    Lung Cancer (Auckl). 2017;8:161-167.
    PubMed     Text format     Abstract available

  50. JAIN RK, Chen H
    Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib.
    Lung Cancer (Auckl). 2017;8:169-177.
    PubMed     Text format     Abstract available


    Mol Cancer Ther

  51. YAMADA T, Amann JM, Tanimoto A, Taniguchi H, et al
    Histone deacetylase inhibition enhances the antitumor activity of a MEK inhibitor in lung cancer cells harboring RAS mutations.
    Mol Cancer Ther. 2017 Oct 27. pii: molcanther.0146.2017.
    PubMed     Text format     Abstract available


    Mol Carcinog

  52. FENG Y, Wang Y, Liu H, Liu Z, et al
    Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer.
    Mol Carcinog. 2017 Oct 26. doi: 10.1002/mc.22748.
    PubMed     Text format     Abstract available

  53. PAN Z, Liu L, Nie W, Miggin S, et al
    Long non-coding RNA AGER-1 functionally upregulates the innate immunity gene AGER and approximates its anti-tumor effect in lung cancer.
    Mol Carcinog. 2017 Oct 25. doi: 10.1002/mc.22756.
    PubMed     Text format     Abstract available


    Nat Rev Cancer

  54. GAZDAR AF, Bunn PA, Minna JD
    Small-cell lung cancer: what we know, what we need to know and the path forward.
    Nat Rev Cancer. 2017 Oct 27. doi: 10.1038/nrc.2017.
    PubMed     Text format     Abstract available

  55. ROTOW J, Bivona TG
    Understanding and targeting resistance mechanisms in NSCLC.
    Nat Rev Cancer. 2017;17:637-658.
    PubMed     Text format     Abstract available


    PLoS One

  56. KIND M, Klukowska-Rotzler J, Berezowska S, Arcaro A, et al
    Questioning the role of selected somatic PIK3C2B mutations in squamous non-small cell lung cancer oncogenesis.
    PLoS One. 2017;12:e0187308.
    PubMed     Text format     Abstract available

  57. FORCELLA M, Oldani M, Epistolio S, Freguia S, et al
    Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
    PLoS One. 2017;12:e0187289.
    PubMed     Text format     Abstract available

  58. SCHMIDT LH, Heitkotter B, Schulze AB, Schliemann C, et al
    Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.
    PLoS One. 2017;12:e0186280.
    PubMed     Text format     Abstract available

  59. OTOSHI T, Kataoka Y, Ikegaki S, Saito E, et al
    Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
    PLoS One. 2017;12:e0185850.
    PubMed     Text format     Abstract available

  60. ZHAO J, Dinkel J, Warth A, Penzel R, et al
    CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation.
    PLoS One. 2017;12:e0182741.
    PubMed     Text format     Abstract available


    Thorax

  61. LUCHTENBORG M, Morris EJA, Tataru D, Coupland VH, et al
    Investigation of the international comparability of population-based routine hospital data set derived comorbidity scores for patients with lung cancer.
    Thorax. 2017 Oct 27. pii: thoraxjnl-2017-210362.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: